Protalix BioTherapeutics [SEP] inception
Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Corporate history.
Protalix BioTherapeutics was established in 1993. It was founded by Yoseph Shaaltiel, who received his Ph.D. in Plant Biochemistry from the Weizmann Institute in Israel and served in the Biology Department of the Israel Defense Forces' Biological and Chemical Center. One of the earliest and largest investors in the company was Phillip Frost.
Miami pharmaceutical maker, Ivax, for $7.4 billion, to Israel-based Teva Pharmaceuticals, in January 2006.
Career Teva Pharmaceutical Industries.
Frost became vice chairman of Teva Pharmaceutical Industries in January 2006, when Teva acquired Ivax Corporation. He was named the chairman of the board of Teva, in March 2010 and was reelected to the position in May 2012 before stepping down in 2015.
Career Protalix BioTherapeutics.
Frost was one of the first and largest investors in Protalix BioTherapeutics, investing $24 million in the company